Literature DB >> 15338314

153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms.

Fernanda Marques1, Krassimira P Guerra, Lurdes Gano, Judite Costa, M Paula Campello, Luís M P Lima, Rita Delgado, Isabel Santos.   

Abstract

A set of tetraaza macrocycles containing pyridine and methylcarboxylate (ac(3)py14) or methylphosphonate (MeP(2)py14 and P(3)py14) pendant arms were prepared and their stability constants with La(3+), Sm(3+), Gd(3+) and Ho(3+) determined by potentiometry at 25 degrees C and 0.10 M ionic strength in NMe(4)NO(3). The metal:ligand ratio for (153)Sm and (166)Ho and for ac(3)py14, MeP(2)py14 and P(3)py14, as well as the pH of the reaction mixtures, were optimized to achieve a chelation efficiency higher than 98%. These radiocomplexes are hydrophilic and have a significant plasmatic protein binding. In vitro stability was studied in physiological solutions and in human serum. All complexes are stable in saline and PBS, but 20% of radiochemical impurities were detected after 24 h of incubation in serum. Biodistribution studies in mice indicated a slow rate of clearance from blood and muscle, a high and rapid liver uptake and a very slow rate of total radioactivity excretion. Some bone uptake was observed for complexes with MeP(2)py14 and P(3)py14, which was enhanced with time and the number of methylphosphonate groups. This biological profile supports the in vitro instability found in serum and is consistent with the thermodynamic stability constants found for these complexes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338314     DOI: 10.1007/s00775-004-0587-3

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  33 in total

1.  Therapeutic radiopharmaceuticals.

Authors:  W A Volkert; T J Hoffman
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Complexones; titration of metals with nitrilotriacetic acid H3X; End point indication through pH effects.

Authors:  G SCHWARZENBACH; W BIEDERMANN
Journal:  Helv Chim Acta       Date:  1948       Impact factor: 2.164

Review 3.  Imaging tumors with peptide-based radioligands.

Authors:  T M Behr; M Gotthardt; A Barth; M Béhé
Journal:  Q J Nucl Med       Date:  2001-06

4.  Tc-99m and Re-186 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models.

Authors:  S Banerjee; G Samuel; K Kothari; P R Unni; H D Sarma; M R Pillai
Journal:  Nucl Med Biol       Date:  2001-02       Impact factor: 2.408

5.  177Lu-EDTMP: a potential therapeutic bone agent.

Authors:  A Ando; I Ando; N Tonami; S Kinuya; K Kazuma; A Kataiwa; M Nakagawa; N Fujita
Journal:  Nucl Med Commun       Date:  1998-06       Impact factor: 1.690

Review 6.  Physical and chemical properties of radionuclide therapy.

Authors:  B W Wessels; C F Meares
Journal:  Semin Radiat Oncol       Date:  2000-04       Impact factor: 5.934

Review 7.  Therapeutic radionuclides: production and decay property considerations.

Authors:  W A Volkert; W F Goeckeler; G J Ehrhardt; A R Ketring
Journal:  J Nucl Med       Date:  1991-01       Impact factor: 10.057

8.  Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.

Authors:  S V Deshpande; S J DeNardo; D L Kukis; M K Moi; M J McCall; G L DeNardo; C F Meares
Journal:  J Nucl Med       Date:  1990-04       Impact factor: 10.057

Review 9.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

Review 10.  Radionuclide cancer therapy.

Authors:  C A Hoefnagel
Journal:  Ann Nucl Med       Date:  1998-04       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.